Silence Therapeutics plc
SLNCF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $24 |
| % Growth | -29% | 57.7% | -99.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $2 |
| Gross Profit | $0 | $0 | $0 | $23 |
| % Margin | 59.7% | 62.1% | 62% | 93.4% |
| R&D Expenses | $21 | $18 | $21 | $20 |
| G&A Expenses | $6 | $5 | $8 | $5 |
| SG&A Expenses | $6 | $5 | $8 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $0 | $0 |
| Operating Expenses | $26 | $24 | $28 | $26 |
| Operating Income | -$26 | -$24 | -$28 | -$3 |
| % Margin | -16,505.7% | -10,697.8% | -20,006.3% | -12.7% |
| Other Income/Exp. Net | $5 | -$3 | -$0 | $27 |
| Pre-Tax Income | -$21 | -$27 | -$29 | $24 |
| Tax Expense | $0 | $0 | $0 | $10 |
| Net Income | -$21 | -$27 | -$29 | $14 |
| % Margin | -13,181.1% | -12,211.6% | -20,091.5% | 58.3% |
| EPS | -0.15 | -0.19 | -0.2 | 0.1 |
| % Growth | 21.1% | 5% | -300% | – |
| EPS Diluted | -0.15 | -0.19 | -0.2 | 0.1 |
| Weighted Avg Shares Out | 142 | 142 | 142 | 139 |
| Weighted Avg Shares Out Dil | 142 | 142 | 142 | 139 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | -$12 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$26 | -$22 | -$20 | $7 |
| % Margin | -16,407.5% | -10,040.6% | -13,950.7% | 29.6% |